Initiate research programs for translational bioinformatics and network pharmacology to support rational drug repositioning and combination therapy from discovery through clinical development.
Identification of at least 6 existing drugs suitable for repurposing and/or combination therapy for AD and ADRD prevention or treatment. The drugs selected for repurposing or combination therapy will be prioritized based on:
evidence that they modulate disease relevant pathways/networks gained from computational and empirical approaches.
preclinical proof-of-efficacy in a relevant model system.
availability of biomarkers to monitor target engagement in humans.
sufficient evidence of safety for the intended target population.
Summary of Key Accomplishments
Novel uses for existing and failed drugs can save time and cost in bringing new therapeutics to individuals. Investigators funded through NIA’s Drug Repurposing and Combination Therapy Development program, have identified over 20 FDA approved drugs with a potential to be repurposed in AD. An example is bumetanide, an FDA approved drug for the treatment of hypertension and edema; based on computational predictions that utilized publicly available genomic and EHR data and experimental work in animal models, this repurposing candidate has the potential to be effective in individuals with AD that carry the ApoE4 risk factor gene.
NIA’s Alzheimer’s Clinical Trials consortium and clinical trials funding initiatives provide a path for the most promising drug repurposing candidates to be evaluated in human trials for AD/ADRD treatment and prevention. NIA’s AD/ADRD clinical trials program has supported the testing of 10 repurposed drug candidates to date.
This information is current as of March 2022.
- Research Implementation Area
- Drug Repurposing and Combination Therapy Development
- PAR-17-032: Translational Bioinformatics Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimer’s Disease (R01)
- PAR-20-156: Translational Bioinformatics Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimer’s Disease (R01 Clinical Trial Optional)
Research Programs and Resources
- Translational Bioinformatics Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimer’s Disease
- Endophenotype Network-based Approaches to Prediction and Population-based Validation of in Silico Drug Repurposing for Alzheimer’s Disease
- Compound repositioning for Alzheimer’s Disease using knowledge graphs, insurance claims data, and gene expression complementarity
- Drug repurposing for Alzheimer's disease using structural systems pharmacology
- An Integrated Reverse Engineering Approach Toward Rapid Drug Repositioning for Alzheimer’s Disease
- Systematic Alzheimer's disease drug repositioning (SMART) based on bioinformatics-guided phenotype screening and image-omics
- ApoE Genotype-Directed Drug Repositioning and Combination Therapy for Alzheimer's Disease
- Harnessing Diverse BioInformatic Approaches to Repurpose Drugs for Alzheimers Disease